AIkido Pharma Inc (AIKI)

[Viewmont]

NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

Research will operate under the direction of Dr. Michael Peters to develop and optimize peptide biomimetics in order to achieve high binding rates of peptide to the RBD of SARS-Cov-2 spike protein at the nanomolar level with demonstrated negligible toxicity through combined computational and experimental efforts. Specifically, point mutations will be conducted in-silico in order to seek to improve the stability and binding properties of these decoy peptides. These optimized, in-silico peptides will be synthesized and experimentally characterized through structure determination, binding to the spike protein, and finally cell challenge assays with SARS-Cov-2. Hoth Therapeutics has exclusive license to this novel peptide COVID-19 therapeutic.

"VCU, through the leadership of Dr. Michael Peters, has made significant strides in the research of the COVID-19 disease," said Mr. Robb Knie, CEO of Hoth Therapeutics. "We look forward to working with VCU in accelerating progress on the development of this intellectual property and in establishing novel treatments to combat the pandemic."

Currently, Dr. Peters is utilizing supercomputers as part of the COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system that scientists can use to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

[Viewmont]

Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment
Hoth has exclusive license to this novel peptide COVID-19 therapeutic
NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

[Viewmont]

Soon we shall see AIKI running!

[gaardo]

Cant stand that guy!

[wolfofmemphis]

Looks like Clay and his merry band st work here.

[Golden Cross]

True...Back over $1 then $2 soon...

[gaardo]

Human trial PR would set this off!

[Golden Cross]

Yep, nicer volume Friday... GLtA $AIKI

[Viewmont]

Very nice! Let's see some action coming up!

[Golden Cross]

$AIKI PSAR flipped bullish on chart Friday

[Viewmont]

Good to see you too BDEZ. Yes I've been holding also. I've seen this go to $15 in two days a while back with extreme news. It's tie for that. LOL.

[Taurus69]

$aiki $1 with news

[BDEZ]

Yeah thanks viewmont and good to see you, i'm holding and have been for quite awhile and will let patience play this out. Lot's more upside i hope.

[Viewmont]

Hi BDEZ, hope you did well today with AIKI. It's long overdue for this to go up.

Good luck!

[ClayTrader]

* * $AIKI Video Chart 06-26-2020 * *

Link to Video - click here to watch the technical chart video

[BDEZ]

Lol..i know how you feel. Well at least we now have a spark.

AIKI

[BDEZ]

Agree...was overdue.

AIKI

[gaardo]

Could have been a better close, but will take it!

[BDEZ]

Nice day today!

AIKI

[Pt3]

news just came out

[gaardo]

No...was just tweeted out by a few people with a lot of followers. Looking for the PR on human trials starting. That will get it going!

[ming1234]

pump and dump?

[keekee]

Lol...idiots making market here. Just noticed this and some a bunch just now. Let's see how far it goes for the rest.....FOOLS FOOLS FOOLS

[lifedealer]

Georgie is this ready to explode?...good call!...RBNW waking up also!

[Viewmont]

I don't see any news today, but the stock is moving up good! 12% up so far.

[Viewmont]

It's moving up nicely today.

[nuclear profitz]

we have some volume, let see if they let it run

[Viewmont]

Needs huge massive NEWS NOW!

[Viewmont]

AIKI still consolidating!

[posilock]

In what year will this happen?

[Viewmont]

AIKI Just a silent monster. Gotta have patience. http://schrts.co/WivcXNMP

[Viewmont]

Thanks!

[missile_systems]

Good Luck to you as well View

[Viewmont]

Too many to mention, patents and medicine in the pipeline, can't remember details. You have to dig in and do DD and be fresh in the know.

Good luck!

[missile_systems]

Could really use it , view.
Any catalyst upcoming?
TY

ghost.

[Viewmont]

http://schrts.co/HDSjQzDP It'll spike real high in a surprising way when nobody's paying attention to its news, looking at its history.

[SeatonBM]

What's the story here? Chart looks great, but seemingly all sells today since the morning bell and morning spike....

[Viewmont]

NEW YORK, June 15, 2020 THERAPEUTICS' SCIENTIFIC ADVISORY BOARD MEMBER AND INVENTOR OF LICENSED NOVEL PEPTIDE COVID-19 THERAPEUTIC, DR. MICHAEL PETERS, PUBLISHES WHITE PAPER
NEW YORK, June 15, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member and inventor of novel peptide COVID-19 therapeutic, Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering, has published a white paper detailing his mappings of the COVID-19 virus and its spike protein.

(PRNewsfoto/Hoth Therapeutics Inc.)

Hoth has licensed technology and intellectual property exclusively from VCU for a novel peptide therapeutic to prevent spike protein binding, which may be a leading cause of COVID-19, and slow its transmission.

The spike in protein plays an important role in attaching to human cells and infecting the body. Researchers at VCU have developed at novel peptide that binds with extremely high affinity to SD1 segment of the SARS-CoV-2 spike protein mimicking its attachment to ACE2. This high binding affinity helps block the spike protein from attaching to the ACE2 surface receptor, thus limiting the transmission of the virus.

The SARS-Cov-2 virion responsible for the current world-wide pandemic COVID-19 has a characteristic Spike protein (S) on its surface that embellishes both a prefusion state and fusion state. The prefusion Spike protein (S) is a large trimeric protein where each protomer may be in a so-called Up state or Down state, depending on the configuration of its receptor binding domain (RBD). The Up state is believed to allow binding of the virion to ACE-2 receptors on human epithelial cells, whereas the Down state is believed to be relatively inactive or reduced in its binding behavior.

Currently, Peters is utilizing supercomputers as part of COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system that scientists can use to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.

About Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

[Viewmont]

HOTH THERAPEUTICS ENTERS INTO EXPANDED SPONSORED RESEARCH AGREEMENT WITH THE GEORGE WASHINGTON UNIVERSITY FOR DERMATOLOGY TREATMENT CANDIDATE WEG232
WEG232 IS A TOPICAL TREATMENT WITH SPECIFIC SUBSTANCE P-RECEPTOR INHIBITOR FOR ERLOTINIB-INDUCED FACIAL DERMATITIS AND HAIR LOSS IN CANCER PATIENTS
NEW YORK, June 16, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announced that it has expanded its sponsored research agreement with the George Washington University (GW) to explore the potential use of WEG232 for topical and/or systemic therapy to counter the dermatological related side-effects of chemotherapy and immunotherapy in cancer patients.

(PRNewsfoto/Hoth Therapeutics Inc.)

The company has increased its commitment to further the science behind this therapeutic with Dr. William Wegliki's lab at GW. Hoth intends to request a Pre-IND meeting with the FDA by year-end.

Hoth continues to develop topical WEG232 formulation for treatment of mild to moderate (grades 1-3) rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy. A recent research study suggested the topical application of WEG232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity.

Future studies will include:

Determining the optimal treatment or pretreatment time of application and the weekly number of applications, eg. 2 or 3/week, of WEG232 to prevent the occurrence of the anticipated skin rash/hair loss.

[stock1ace1]

*** breakout !

[Warchest]

.90 break and then $1.25 range !!!

[georgie18]

Your very welcome...yes...

[lifedealer]

Thx for this one Georgie...you still bullish on rbnw?

[georgie18]

AIKI...89...P/M...

georgie18 Saturday, 06/06/20 06:23:21 AM
Re: Citrati post# 7743 0
Post #
7744
of 7769
AIKI...73...Consolidation Channel Breakout setting up here on the Bollie Squeeze...as the Psar is ready to flip to a Bullish Buy Position...

As of May 13, 2020, there were 34,920,219 shares of the Company’s common stock issued and outstanding.

https://www.otcmarkets.com/filing/html?id=14148986&guid=JvaHUnzRuvrmGth

Chart...http://schrts.co/nxCbhCuz

Been accumulating AIKI for months also collected a nice Divvy of HOTH shares currently priced at $2.80...

[missile_systems]

Wow...thank you ,view.
I've been away at least 4 yrs. I held spex when it was run by Rockstar Holdings, I believe was the name.Lolol

[Viewmont]

http://schrts.co/inQJSiRq It's time for AIKI to come up with explosive news and go to $5 plus again .

[Viewmont]

People are watching silently. AIKI is now SPEX, name changed.
It looks like you have to do some DD to catch up. HOTH is a subsidiary of AIKI and some good updates.

https://aikidopharma.com/

https://www.otcmarkets.com/stock/AIKI/disclosure


Good luck!

[Viewmont]

SPEX changed ticker name to AIKI.

[missile_systems]

is spex defunct?
I was searching it and this Aiki ticker came up.
Just trying to get an idea of what's going on with this ticker these days.
Thanks for any help !

ghost.

[missile_systems]

Hey view...any upcoming catalysts here?
Seems way undervalued and very quiet on the message board as well. What gives ?